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Summary
OBJECTIVES: To describe disease characteristics and
treatment modalities in a multidisciplinary cohort of sys-
temic lupus erythematosus (SLE) patients in Switzerland.
METHODS: Cross-sectional analysis of 255 patients in-
cluded in the Swiss SLE Cohort and coming from centres
specialised in Clinical Immunology, Internal Medicine,
Nephrology and Rheumatology. Clinical data were collec-
ted with a standardised form. Disease activity was assessed
using the Safety of Estrogens in Lupus Erythematosus Na-
tional Assessment-SLE Disease Activity Index (SELENA-
SLEDAI), an integer physician’s global assessment score
(PGA) ranging from 0 (inactive) to 3 (very active disease)
and the erythrocyte sedimentation rate (ESR). The relation-
ship between SLE treatment and activity was assessed by
propensity score methods using a mixed-effect logistic re-
gression with a random effect on the contributing centre.
RESULTS: Of the 255 patients, 82% were women and 82%
were of European ancestry. The mean age at enrolment was
44.8 years and the median SLE duration was 5.2 years.
Patients from Rheumatology had a significantly later dis-
ease onset. Renal disease was reported in 44% of patients.
PGA showed active disease in 49% of patients, median
SLEDAI was 4 and median ESR was 14 millimetre/first
hour. Prescription rates of anti-malarial drugs ranged from
3% by nephrologists to 76% by rheumatologists. Patients
regularly using anti-malarial drugs had significantly lower
SELENA-SLEDAI scores and ESR values.
CONCLUSION: In our cohort, patients in Rheumatology
had a significantly later SLE onset than those in Neph-
rology. Anti-malarial drugs were mostly prescribed by
rheumatologists and internists and less frequently by neph-
rologists, and appeared to be associated with less active
SLE.
Key words: lupus; Switzerland; cohort;
hydroxychloroquine; disease activity
Introduction
Systemic lupus erythematosus (SLE) is a chronic disease
with a waxing and waning course, mainly affecting woman
in their fertile years. Loss of tolerance to a variety of auto-
antigens including, but not exclusively, double stranded
DNA and nucleosomes is characteristic of SLE and reflects
defective T and B cell threshold of activation. Cells of the
innate immune system and their receptors are also thought
to play a major role in disease initiation and flares. Envir-
onmental cues interacting with a predisposed genetic back-
ground are considered fundamental for setting in motion
the immunological alterations that will result in overt dis-
ease.
The estimated incidence of the disease in western European
countries ranges from 2.2 to 5 / 100,000 inhabitants and the
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prevalence from 20.5 to 91 /100,000 [1]. Clinical presenta-
tion may involve tissues and organs as diverse as the skin,
the kidneys, the central and peripheral nervous system, the
haematological system and the joints. Thus, patients with
SLE are taken care of by different medical specialities.
The care of SLE patients by various medical disciplines
contributes to major differences in assessing disease activ-
ity, damage and treatment. The Swiss SLE Cohort Study
(SSCS) aims at identifying the clinical characteristics of
SLE patients followed in Switzerland, their disease burden,
and treatment. We report here the results from a cross-sec-
tional study of the first 255 patients with definite SLE in-
cluded in this cohort, focusing on the differences in the
prescription of SLE-specific drugs between medical discip-
lines and their impact on global disease activity.
Methods and data collection
Patients
A cross-sectional collection of data was performed
between April 2007 and March 2012 in the Swiss SLE
Cohort Study (SSCS) [2]. We prospectively included 255
adult patients with prevalent SLE defined according to
the American College of Rheumatology (ACR) criteria [3,
4]. The cohort study was approved by the ethics review
boards of all participating institutions and all patients gave
their written informed consent. Patients included originated
from Clinical Immunology, Internal Medicine, Nephro-
logy, and Rheumatology tertiary centres located both in the
French and German-speaking regions of Switzerland.
Data on patient’s age, sex, ethnicity and family history of
SLE, dates of first lupus manifestation and diagnosis, clin-
ical and biological characteristics at baseline, disease activ-
ity, laboratory parameters, treatment modalities and co-
morbidity were collected. SLE manifestations were defined
using the 1982 ACR classification criteria, which were
updated in 1997 [3, 4]. Disease activity was assessed by
the Systemic Lupus Erythematosus Disease Activity Index
(SLEDAI) score with the Safety of Estrogens in Lupus
Erythematosus National Assessment (SELENA) modifica-
tion [5]. Laboratory parameters were assessed by the indi-
vidual centres. For the purpose of the SELENA-SLEDAI,
positivity for anti-dsDNA antibodies and reduced comple-
ment levels were defined independently of the methodo-
logy used by a test result above and below normal range,
respectively. Furthermore, we used a Physician’s Global
Assessment (PGA) score with a 4–point-scale of disease
activity, ranging from 0 (inactive disease) to 3 (very act-
ive disease). Both scores were used with a 30–day window
[6]. Medication was detailed for disease-modifying drugs
(DMARD's) taken. DMARD's were classified in three
groups: systemic corticosteroids, anti-malarial drugs and
immunosuppressive agents. Regular use of these medic-
ations was defined by prescription at study visit, during
the preceding 4 weeks and previously. The anonymous
clinical data were stored in an online database (ht-
tps://www.slec.ch).
Primary and secondary outcomes
Our primary outcome was the assessment of global disease
activity by the SELENA-SLEDAI score at study visit. Se-
condary outcomes were the 4–point PGA scale and the
erythrocyte sedimentation rate (ESR) at study visit. Vari-
ables for SLE disease activity were dichotomised as fol-
lows: SELENA-SLEDAI <4 (inactive) and >= 4 (active),
in analogy to what has been published for the
SLEDAI-2000 score, (7) PGA <1 (inactive) and >= 1
(moderately active to very active), and ESR <20 mm/1st
hour and >= 20 mm/1st hour.
Statistical analysis
Quantitative variables were expressed as the mean ± stand-
ard deviation (SD). We compared quantitative variables by
presence/absence of the outcome using Student’s t-test or
nonparametric tests depending on the application criteria.
We also compared the mean values of activity indices by
DMARD use. Categorical variables were compared by out-
come and also by the type of DMARD's using the chi-
square test or, when appropriate, Fisher’s exact test. We
provided Pearson’s correlation coefficients between the
SLEDAI and PGA scores, SLEDAI score and ESR and
also between PGA and ESR.
We assessed the association between the use of specific
drugs and the activity of the disease, using SELENA-
SLEDAI, PGA and ESR. We first created propensity scores
for the three different treatments in order to adjust on po-
tential confounders for the use of anti-malarials, corticos-
teroids and immunosuppressive agents [8]. We used the
same confounders for the three propensity scores: age, dis-
ease duration, gender, disease characteristics as defined
by ACR Criteria (renal disease, neuropsychiatric SLE,
haematologic involvement, arthritis, serositis and photo-
sensitivity), and renal insufficiency defined by serum cre-
atinine levels above 100 umol/l.
As the cohort included patients from 8 different Swiss hos-
pitals, we expected some variability between centres. Thus,
we used a mixed effect logistic regression model with a
random effect on the centre in order to assess the asso-
ciation between disease activity and DMARD type used
after adjustment on the relative propensity score categor-
ised following their quantiles. p-values <0.05 (two-sided)
were judged significant. Statistical analysis was performed
using STATA Version 12.0 software (StataCorp LP, College
Station, TX).
Results
The 255 prospectively included patients with prevalent
SLE had their first study visit between April 11th, 2007
and March 21st, 2012. Patient’s baseline characteristics are
shown in table 1. ACR criteria present prior to or at inclu-
sion are shown in figure 1. Renal disease, as defined by
the ACR criteria, was present in 112 (44%) of patients, of
which 4 were on dialysis and 2 had received renal trans-
plants. A total of 29 (11%) patients had either psychosis
or seizures as a neuropsychiatric SLE manifestation. The
median SELENA-SLEDAI score at the time of visit was 4
(IQR 2–10). It scored less than 4 points in 103 (40%) pa-
tients. According to PGA, SLE was recorded as “inactive”
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in 128 (51%) of patients. Correlation between SELENA-
SLEDAI and PGA was high (r = 0.5, p <0.001). ESR at vis-
it was measured in 202 patients, with a median value of 14
(IQR 6–30) millimetres in the first hour (mm/1st hr). There
was moderate correlation between ESR and SELENA-
SLEDAI (r = 0.22, p = 0.02) and between ESR and PGA
(r = 0.34, p <0.001). No significant correlation was found
between disease duration and SELENA-SLEDAI or ESR.
Complement levels at the time of visit were low in 86/219
(39%) and anti-dsDNA antibodies present in 97/217 (45%)
of the patients.
SLE care was provided by internists and immunologists in
130 (51%), rheumatologists in 90 (35%) and by nephro-
logists in 35 (14%) of the cases. Patient’s characteristics
by contributing medical specialty are shown in table 2.
Age at diagnosis was a median of 31.6 (inter-quartile range
(IQR) 23.3–44.2) years for patients from Internal Medicine
and Immunology, 24.4 (IQR 21–38.4) years for patients
from Nephrology and 39.9 (IQR 28.4–51.2) years for pa-
tients from Rheumatology (p = 0.001). First manifestations
of SLE had occurred at a median of 30 (IQR 20.9–41.1)
years in patients from Internal Medicine and Immunology,
23.4 (IQR 19.1–38.3) years from Nephrology and 39.3
Figure 1
American College of Rheumatology Criteria fulfilled at inclusion in
255 patients with systemic lupus erythematosus.
Figure 2
Disease activity in relation to treatment preceding visit (past month
and before).
A: SELENA-SLEDAI score at study visit. Differences are statistically
significant for antimalarial drugs (p <0.001) and corticosteroids (p =
0.024).
B: Erythrocyte sedimentation rate at study visit, in millimeter 1st
hour. Differences are statistically significant for antimalarial drugs (p
= 0.002)
(IQR 25.5–51.7) years in patients from Rheumatology (p =
0.003). Median time from first SLE manifestations to dia-
gnosis was 3 (IQR 0–12) months and did not differ between
disciplines.
Disease manifestations are compared to other SLE cohorts
in table 3.
Disease-specific treatment is shown in table 4. Of the 244
patients in whom SLE medication was detailed at the time
of study visit and previously, 43 (17.6%) were on anti-mal-
arial drugs (AM) alone, 40 (16.4%) on AM, systemic cor-
ticosteroids (CS) and immunosuppressive agents (IS) in as-
sociation, 35 (14.4%) on AM and CS, 21 (8.6%) on CS
alone, 20 (8.2%) on CS and IS, 12 (4.9%) on IS and AM,
and 4 (1.6%) on IS alone. A total of 62 (25.4%) patients
had either stopped SLE specific medication previous to the
visit or had been newly treated, and 7 (2.8%) had never
been treated for SLE. Anti-coagulants and platelet inhib-
itors were taken by 44.7% of patients (acetylsalicylic acid
in 25.2%, coumarine derivatives in 18.3%, clopidogrel in
2.8% and low molecular weight heparin in 2.4%). The use
of these agents was twice as frequent in the 112 patients
with anti-phospholipid antibodies.
Regular use of AM was noted in 130 (53%) patients, with
prescription rates ranging from 68 (76%) patients in the
care of a rheumatologist to 61 (48%) patients in the care
of internists and immunologists, and 1 (3%) patient in the
care of nephrologists (p <0.001). Of the 126 patients in
whom the type of AM was known, 120 (95%) had hy-
droxychloroquine and 6 (5%) chloroquine.
IS were regularly taken by 43 (48%) patients from Rheum-
atology, 29 (23%) patients from Internal Medicine and Im-
munology and 6 (18%) patients from Nephrology (p
<0.001). The choice of IS was similar across specialties
with the exception of more frequent use of azathioprine
(AZA) and reciprocal lesser use of mycophenolate mofetil
(MMF) by rheumatologists, when compared to other spe-
cialties (49% AZA and 28% MMF for Rheumatology vs.
28% AZA and 55% MMF for Internal Medicine and Im-
munology vs. 17% AZA and 83% MMF for Nephrology).
CS were regularly taken by 44 (49%) patients from Rheum-
atology, 65 (52%) patients from Internal Medicine and Im-
munology and 7 (24%) patients from Nephrology. The ratio
of patients treated with IS and AM to IS without AM was
4:1 in Rheumatology and 2:1 in Internal Medicine and Im-
munology. In Nephrology, no patient had a combination of
IS and AM.
The association of regular use of AM, CS and IS to disease
activity is shown in figure 2. Patients regularly using AM
had lower disease activity scores: median SELENA-
SLEDAI score of 3.5 (IQR 1–8) versus 6 (IQR 2–13) (p
<0.001) and median PGA score of 0 versus 1 (p = 0.09)
in those without AM. The association of AM with lower
disease activity was particularly evident in patients with no
additional IS or CS: SELENA-SLEDAI <4 in 26/43 (61%)
of patients with AM versus 25/69 (36%) without AM (p =
0.012).
In contrast, patients regularly receiving CS had a higher
disease activity: median SELENA-SLEDAI score of 5.5
(IQR 2–10.75) versus 4 (IQR–2–8 (p = 0.024) and median
PGA 1 versus 0 (p <0.001) in those without CS. For regular
use of IS, no significant change in global disease activity
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was found compared to those not receiving IS: median
SELENA-SLEDAI score of 4 (IQR 2–10.5) versus 4 (IQR
2–9.75). When investigated for the type of IS, patients un-
der continuous treatment with MMF had a higher disease
activity (median SLEDAI 8 versus 4; p = 0.006) than those
treated with other drugs. These differences were not seen
for patients treated with AZA.
When assessing patients treated with a combination of CS
and IS, those with additional AM also had less active dis-
ease than those without AM: SELENA-SLEDAI <4 in 15/
40 (38%) with AM compared to 2/20 (10%) without AM (p
= 0.034).
Median ESR at the study visit was 11 (IQR 6–20) mm/1st
hr in patients regularly taking AM, compared to 19.5 (IQR
9–41.5) in those without this treatment (p = 0.002). On the
other hand, patients regularly treated with CS or IS had no
significant differences in ESR values compared with those
without these treatments.
In order to avoid bias due to the comparison of disease
activity in patients treated with anti-malarial drugs to a
non-randomised control group and also to centre- or
discipline-specific differences in the prescription of AM
(e.g. patients with more severe SLE being prone to higher
disease activity and also more susceptible to be treated in
centres and by specialists with lower prescription rates for
AM), we generated a propensity score to adjust the drug
use to potential confounders and secondarily performed a
mixed-effect logistic regression model with a random ef-
fect on the centre. Using the SELENA-SLEDAI as the de-
pendent variable in this model, the random effect on the
centre was significant (p = 0.0016). For AM use, the odds
ratio to have a SELENA-SLEDAI value >= 4 was 0.49
(0.26–0.95 confidence interval (CI); p = 0.034). Using the
ESR as dependent variable in this model, the random effect
on the centre was not significant (p = 0.99). For AM use,
the odds ratio to have an ESR value ≥20 mm/1st hour was
0.37 (0.19–0.73 CI; p = 0.004).
Discussion
The main objectives of this study were to characterise pa-
tients included in the Swiss SLE cohort and to assess differ-
Table 1: Disease characteristics at baseline in 255 patients with systemic lupus erythematosus (SLE).
Sex, female/male (%) 210/45 (82/18)
Ethnicity
Caucasian, no. (%) 210 (82.4)
African, no. (%) 9 (3.5)
Asian, no. (%) 19 (7.5)
Other, no. (%) 6 (2.4)
Unknown, no. (%) 11 (4.3)
First-degree relatives with SLE, no. (%) 25 (12.9)a
Age at SLE diagnosis, mean ± SD (range) years 36.4 ± 15.5 (12–87)
Age at first SLE manifestation, mean ± SD (range) years 34.5 ± 16.0 (9–86)
Body mass index at time of visit, mean ± SD (range) 25.4 ± 5.1 (16.9–41.0)
Active smoker at time of visit, N (%) 44 (22.3)b
Disease activity at the time of visit and past 4 weeks
SELENA-SLEDAI, mean ± SD (range) 7.1 ± 8.0 (0–42)
Physician's global assessment, mean ± SD (range) 0.7 ± 0.8 (0–3)
Biological values at the time of visit
Erythrocyte sedimentation rate, mean ± SD (range), mm/1st hr 22.8 ± 24.2 (1–150)
Plasma creatinine, mean ± SD (range), μmol/l 87 ± 69.4 (36–716)
SD = Standard Deviation, SELENA-SLEDAI = Systemic Lupus Erythematosus Disease Activity Index score with the Safety of Estrogens in Lupus
Erythematosus National Assessment modification
a in 194 patients; b in 197 patients
Table 2: Disease characteristics by medical specialties in 255 patients with systemic lupus erythematosus (SLE).
Medical specialty n Age at inclusion,
mean ± SD
(range), years
SLE duration,
median (IQR),
years
n (%) with
disease onset
after 50 years
ACR Criteria
fulfilled, median
(IQR)
n (%) with renal
disease
SELENA-SLEDAI,
median (IQR)
Clinical Immunology & Internal
Medicinea
130 43.5 ± 14.5
(18–85)
5.3 (1.2–12.5) 21/125 (17) 5 (5–6) 62 (48) 6 (2–11.25)
Nephrologyb 35 39.6 ± 12.3
(21–68)
10.5 (4–14.2) 3/35 (9) 6 (5–8) 29 (83) 6 (2–13)
Rheumatologyc 90 48.3 ± 14.4
(20–89)
3.5 (2–10) 17/67 (25) 4 (4–5) 21 (23) 2 (0–6)
Total 255 44.8 ± 14.4
(18–89)
5.2 (1.7–12.8) 41/227 (18) 5 (4–6) 112 (44) 4 (2–10)
a Immunology and Allergy Geneva and Sion (N = 65), Internal Medicine Basel (N = 51), Immunology and Allergy Lausanne (N = 14).
b Nephrology Bern (N = 21), Nephrology Zurich (N = 14).
c Rheumatology Sankt Gallen (N = 78), Rheumatology Schaffhausen (N = 12).
The number of subjects at each center corresponds to the number of patients with full dataset at the time of evaluation and at least 4 components of the American College
of Rheumatology (ACR) diagnostic criteria for Systemic Lupus Erythematosus (SLE).
SD = Standard Deviation; SELENA-SLEDAI = Systemic Lupus Erythematosus Disease Activity Index with the Safety of Estrogens in Lupus Erythematosus National
Assessment modification
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ences in SLE management among medical specialties. Our
SLE cohort is the first multidisciplinary one in Switzerland.
The subjects originated from eight different centres. All
the investigators were based at tertiary devoted academic
centres. Physicians involved were internists and/or clinical
immunologists in 51%, rheumatologists in 35% and neph-
rologists in 14% of the cases. The largest European cohort
so far is the Euro-Lupus cohort with 1000 patients, whose
baseline characteristics are here used as reference [9]. A
total of 86% of our patients were of European ancestry,
compared with 97% in the Euro-lupus cohort. Addition-
ally, 82% of our patients were women, in accordance with
the female preponderance reported by others. With a mean
age of 45 years at inclusion, patients were an average of 7
years older than in the Euro-lupus cohort, but very simil-
ar to the mean age of 44.3 years reported in the CaNIOS/
1000 faces of SLE cohort [10]. In SSCS we did not include
paediatric patients, and in addition 41/227 (18%) of our pa-
tients developed SLE after the age of 50 years, compared
to 9% in the Euro-lupus cohort, 10.5% in the CaNIOS
cohort, and up to 39.3% in Lugo, Spain [11]. Whether
the larger proportion of late-onset SLE in our cohort re-
flects changes with time in SLE expression in Europe re-
mains to be established. We also found a significant dif-
ference in age at disease onset depending on the medical
specialty involved. In patients included by nephrologists,
first manifestations of SLE had occurred on average 15
years earlier than in patients from Rheumatology. Also,
renal involvement was reported to be 83% in patients from
Nephrology, compared to 23% of patients from Rheumat-
ology. This is in accordance with the observation that in
SLE, nephritis affects mostly young individuals and oc-
curs early during the disease course [12]. Consistently with
previous reports, the female predominance in this group
of elderly SLE patients was less pronounced, with a fe-
male/male ratio of 2/1 [13]. The prevalence of most disease
characteristics matched with other cohorts, in particular the
proportion of patients suffering from photosensitivity, or-
al ulcers, nephropathy, arthritis, serositis and haematolo-
gical involvement. Regarding serological findings, 98% of
patients had antinuclear antibodies (ANA), 68% had anti-
bodies to double-stranded DNA and 19% anti-Sm antibod-
ies. These proportions of auto-antibodies are also consist-
ent with those found in the Euro-lupus cohort. Positivity
of anti-phospholipid antibodies defined by either antibod-
ies to cardiolipin or beta2–glycoprotein or presence of a
Table 3: Disease characteristics at baseline in comparison with other cohorts.
Authors Petri et al. [31] Wang et al. [32] Alarcon et al. [33] Cervera, et al. [10] Present study
Number of subjects 574 539 555 1000 255
Region USA Asia USA Europe Switzerland
Malar rash, no. present (%) 331 (58) 410 (76) 322 (58) 579 (58) 104 (41)
Discoid lesions, no. present (%) 162 (28) 30 (6) 107 (19) 104 (10) 52 (20)
Photosensitivity, no. present (%) 335 (58) 222 (41) 334 (60) 453 (45) 119 (47)
Oral ulcers, no. present (%) 219 (38) 185 (34) 293 (53) 238 (24) 67 (26)
Arthritis, no. present (%) NR 272 (51) 489 (88) 840 (84) 181 (71)
Nephropathy, no. present (%) 319 (56) 399 (74) 223 (40) 393 (39) 112 (44)
Serositis, no. present (%) NR NR NR 364 (36) 74 (29)
Neurologic involvement, no. present (%) NR 123 (23) 67 (12) 268 (27) 29 (11)a
ANA positive, no. positive (%) NR NR NR 963 (96) 250 (98)
Anti-dsDNA antibodies, no. positive (%) NR NR NR 779 (78) 173 (68)
Anti-phospholipid antibodies, no. positive
(%)
NR NR NR 112 (44)
Anti-Sm antibodies, no. positive (%) NR NR NR 105 (10) 47 (18)
a based on history of psychosis or epilepsy related to SLE
ANA = Anti-nuclear antibodies, dsDNA = doubles-stranded DNA, NR = not reported
Table 4: Treatment in 255 patients with systemic lupus erythematosus.
Medication Used during past month and before
Systemic corticosteroids, no. (%) 116/244 (48)
Oral daily prednisone equivalent at study visit, mean ± SD (range), mg 12.3 ± 11.2 (2–60)
Parenteral corticosteroids in the preceding month, no. (%) 3 (3)
Antimalarial drugs, N (%) 130/247 (53)
Hydroxychloroquine, no. (%) 120 (95)
Chloroquine, no. (%) 6 (5)
Immunosuppressants, no. (%) 78/252a (31)
Mycophenolate, no.b 33
Azathioprine, no. 29
Methotrexate, no. 9
Cyclophosphamide, no. 3
Rituximab, no. 1
Other, no. 4
Non-steroidal anti-rheumatic drugs on a daily basis, no. (%) 40/231 (16.6)
a one patient had more than one immunosuppressive drug
b includes mycophenolic acid
SD = Standard deviation
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lupus anticoagulant prior or at the time of study visit, was
found in 45% of our patients. Thus, aside from the older
age at inclusion, patient characteristics in our cohort are
comparable to those in the Euro-lupus cohort. Although
SLE duration in our cohort was highly variable, we were
able to capture several patients with active disease after
many years of evolution. SELENA-SLEDAI and ESR val-
ues were not correlated with disease duration, thus reinfor-
cing the concept that SLE has not the tendency to wane
with time.
We focused on the SLE-specific treatment. Overall, 53% of
patients in our study were taking anti-malarial drugs on a
regular basis, with hydroxychloroquine (HCQ) being pre-
scribed in 95% of cases. This proportion is comparable to
major SLE trials, in which 50% of patients were treated
with anti-malarial drugs [14]. Of interest, HCQ prescrip-
tion varied significantly between centres and medical spe-
cialties. In particular, 76% of patients in the care of rheum-
atologists were taking anti-malarial drugs, compared to 3%
in the care of nephrologists. Others have reported important
differences in anti-malarial drug prescription rates, which
are particularly high in patients treated by rheumatologists
and low in non-rheumatologist disciplines [15–18]. It could
be argued that patients in the care of rheumatologists had
less severe SLE and were more likely to be treated with
anti-malarial drugs, thus introducing an indication bias.
However, anti-malarials were evenly prescribed in indi-
viduals taking or not immunosuppressive agents and/or
systemic corticosteroids. While anti-malarials appeared
particularly associated with low disease activity in patients
without other treatments, there was still an association with
lower SELENA-SLEDAI values when combined with im-
munosuppressive agents and systemic corticosteroids. The
disparity of anti-malarial drug prescription may be ex-
plained by the fact that rheumatologists were introduced
earlier to these agents and that their guidelines recommend
to consider them for all SLE patients [19, 20]. Indeed, anti-
malarial drugs have been traditionally regarded as indic-
ated in mild SLE with skin and joint involvement [21] and
as ineffective in more severe disease. However, newer data
suggest that all SLE patients may benefit from early and
long-lasting treatment with anti-malarial drugs [22].
The present study found that the regular use of HCQ was
associated with lower disease activity, as expressed by
SELENA-SLEDAI values below 4 and an ESR below 20
mm/1st hour. This contrasted with regular use of systemic
corticosteroids, which was associated with more active
SLE. Although an elevated ESR is not specific for active
SLE, this simple and inexpensive laboratory parameter has
a very good sensitivity [23]. Furthermore, ESR has been
shown to be significantly associated with SLE flares in
the subsequent year [24]. The SELENA-SLEDAI score on
the other hand depends on the training and the experien-
ce of the assessing physician. Putting a random effect on
the centre in the regression model assessing the SELENA-
SLEDAI had a statistically significant effect, suggesting
that there are major differences in this variable between
centres arising either from utilisation of this tool or SLE
severity. However after adjustment there was still a tend-
ency to lower SELENA-SLEDAI values in patients treated
with anti-malarial drugs, possibly pointing to a therapeutic
effect. PGA values were also lower in patients treated with
anti-malarial drugs, although the association was not sig-
nificant. We used a 4–point Likert-like scale for PGA and
it is likely that this tool was not sensitive enough to assess
lower disease activity. Other limitations of our study in-
clude the lack of precise information on the duration of
corticosteroids and immunosuppressive treatment received
since SLE diagnosis as well as differences in the methodo-
logies used to assess immunologic parameters, which was
done by individual centres. Of interest, in our cohort the
use of immunosuppressant agents was not associated with
lower disease activity. While at first sight this may be sur-
prising, it reflects the experience of other centres in which
the use of immunosuppressant agents was independently
associated with chronically active or relapsing remitting
disease [25]. In particular, higher disease activity was re-
corded specifically among individuals taking MMF, which
may reflect the preferential use of this compound in most
severe cases, for instance in individuals with renal disease,
as reflected by higher frequency of MMF use among neph-
rologists.
Others have shown that HCQ is associated with lower SLE
activity. A Canadian randomised placebo-controlled study
of 47 SLE patients receiving HCQ showed an increased
risk of clinical flares of 2.5 (95%-CI 1.08–5.58) in the 6
months after HCQ discontinuation [26]. In patients treated
with mycophenolate mofetil for membranous lupus neph-
ritis, HCQ was an independent predictor of complete renal
remission, with a remission rate 5.2 times higher than those
not receiving HCQ (95% CI 1.2–22.2) [27]. Besides con-
trolling disease activity, HCQ may have several other be-
neficial effects in SLE patients, such as prevention of car-
diovascular events [28], thrombotic events [29], diabetes
[30] decreased bone loss due to corticosteroids [31], and
reducing the risk of malignancy [32]. Thus, HCQ reduces
the risk of overall damage accrual [33], and appears to in-
crease survival in SLE patients [34, 35]. Most SLE patients
are women in child-bearing age and for them, HCQ is of
particular interest in pregnancy and lactation, as it is con-
sidered safe and prevents SLE flares during this critical
period [22]. It is therefore important to consider the use of
anti-malarials to improve the treat-to-target strategy in the
context of SLE [36].
In summary, our study has documented substantial differ-
ences in the rate of prescription of anti-malarials for SLE
across medical disciplines in Switzerland and provides cir-
cumstantial evidence that anti-malarials are associated with
lower SLE disease activity. A longitudinal study is planned
to confirm the impact of HCQ treatment on SLE activity
and damage accrual in our cohort population.
Key messages
SLE patients with renal involvement have an earlier dis-
ease onset.
Anti-malarial drugs for SLE are infrequently used by non-
rheumatologists.
SLE disease activity is lower in patients treated with anti-
malarial drugs.
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Figures (large format)
Figure 1
American College of Rheumatology Criteria fulfilled at inclusion in 255 patients with systemic lupus erythematosus.
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Figure 2
Disease activity in relation to treatment preceding visit (past month and before).
A: SELENA-SLEDAI score at study visit. Differences are statistically significant for antimalarial drugs (p <0.001) and corticosteroids (p = 0.024).
B: Erythrocyte sedimentation rate at study visit, in millimeter 1st hour. Differences are statistically significant for antimalarial drugs (p = 0.002)
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